Study of ORJ-001 for the Treatment of IPF

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.
Epistemonikos ID: d20729375e2de4f1e0d5bc42367aa2a0616b2993
First added on: Oct 10, 2026